BarryMJFowlerFJO'LearyThe American Urological Association symptoms index for benign prostatic hyperplasia. Journal of Urology1992;148: 1549–1557.
2.
McLoughlinJGillKPAbelPDWilliamsG. Symptoms versus flow rates versus urodynamics in the selection of patients for prostatectomy. British Journal of Urology1990;66: 303–305.
3.
GormleyGJStonerEBruskewitzRCThe effect of finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine1992;327: 1185–1191.
4.
RoehrbornCGPredicting the outcome of medical therapy for BPH. Results of a meta analysis. EAU Congress Newsletter1996;Sept 1.
5.
MooreEBrackenBBremerWProscarR five year experience. European Journal of Urology1995;28: 304–309.
6.
ElliotHLReap the benefit of reducing blood pressure. Health and Aging1996;1: 45–48.
StottMAAbramsP. Indoramin in the treatment of prostatic bladder outflow obstruction. British Journal of Urology1991;67: 499–501.
9.
KawabeKUenoATakimotoYAsoYKatoH. YM617 Clinical Study Group. Use of an alpha-1 blocker, YM617, in the treatment of benign prostatic hypertrophy. Journal of Urology1990;144: 908–911.
10.
AbramsPSchulmanCCVaageS, For the European Tamsulosin Study Group. The efficacy and safety of 0.4 mg tamsulosin once daily in symptomatic BPH. Journal of Urology1995;153: (183): 274A.
11.
LeporHTamsulosin Investigator Group. Clinical evaluation of tamsulosin, a prostate selective alpha 1c antagnoist. Journal of Urology1995;153: (182): 274A.
12.
WildeMIFittonASorkinEMTerazosin. A review of its pharmacodynamic and pharmcokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Ageing1993;3: 258–277.
13.
KaplanSADoxazosin in the older male: Efficacy in treating benign prostatic hyperplasia. European Journal of Urology1996;29 (suppl 1): 17–23.
14.
LeporHWilligardWPBarryMJThe efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. New England Journal of Medicine1996;335: 533–539.
